NasdaqGS:AGIOBiotechs
Will EU Thalassemia Approval for PYRUKYND Redefine Agios Pharmaceuticals' (AGIO) Mitapivat-Centric Investment Narrative?
Earlier in May 2026, the European Commission granted marketing authorization for Agios Pharmaceuticals’ PYRUKYND (mitapivat) to treat anemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, making it the only approved medicine across all EU member states for this broad thalassemia population.
This decision not only broadens PYRUKYND’s labeled use beyond pyruvate kinase deficiency but also deepens Agios’ footprint in rare hematologic diseases...